1404 ET - Regeneron missed analysts' 1Q sales and earnings targets, driven by a 26% decline in sales of Eylea, the company's blockbuster vision-loss drug. Doctors are opting for lower-cost alternatives, in part because of problems Medicare patients are having getting copay assistance from nonprofit foundations funded by the pharmaceutical industry. Regeneron is trying to get other drugmakers to match its donations to the foundations so their programs are better funded, CEO Leonard Schleifer tells analysts. Regeneron sinks 7%; the stock has fallen 36% over the past 12 months as the company adjusts to generic competition for Eylea. (joseph.walker@wsj.com)
(END) Dow Jones Newswires
April 29, 2025 14:04 ET (18:04 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.